ESALF:OTC-Eisai Co. Ltd (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 43.67

Change

+1.55 (+3.68)%

Market Cap

USD 11.50B

Volume

1.33K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKKGY Merck KGaA ADR

-0.30 (-0.82%)

USD 79.59B
MKGAF MERCK Kommanditgesellschaft au..

-2.50 (-1.37%)

USD 77.98B
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD 41.30B
HLNCF Haleon plc

-0.02 (-0.50%)

USD 37.62B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 18.32B
SGIOY Shionogi & Co Ltd ADR

-0.09 (-0.78%)

USD 13.81B
SGIOF Shionogi & Co. Ltd

N/A

USD 13.81B
ESAIY Eisai Co. Ltd.

-0.12 (-1.10%)

USD 12.54B
IPSEY Ipsen SA ADR

N/A

USD 10.63B
IPSEF Ipsen S.A

N/A

USD 10.63B

ETFs Containing ESALF

1638:TSE 6.64 % 0.00 %

N/A

N/A
1621:TSE NEXT FUNDS TOPIX-17 Pharm.. 0.00 % 0.00 %

-40.00 (0%)

USD 2.53B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.88% 40% F 34% F
Dividend Return 1.20% 33% F 31% F
Total Return -9.68% 40% F 35% F
Trailing 12 Months  
Capital Gain -27.59% 55% F 37% F
Dividend Return 1.95% 27% F 26% F
Total Return -25.64% 55% F 37% F
Trailing 5 Years  
Capital Gain -48.32% 76% C+ 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.32% 76% C+ 38% F
Average Annual (5 Year Horizon)  
Capital Gain 1.58% 58% F 42% F
Dividend Return 46.30% 77% C+ 75% C
Total Return 44.72% 86% B+ 96% N/A
Risk Return Profile  
Volatility (Standard Deviation) 71.09% 51% F 40% F
Risk Adjusted Return 65.12% 99% N/A 94% A
Market Capitalization 11.50B 98% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.